Suporte

Patient segmentation strategies within the dry age-related macular degeneration market are critically important for therapeutic development, clinical trial design, regulatory approval strategies, and commercial positioning, as different disease stages present distinct pathophysiological characteristics, progression risks, and potential responsiveness to various therapeutic interventions currently under investigation. The dry age related macular degeneration amd market segment encompasses early, intermediate, and advanced dry AMD stages, each representing different patient populations with varying clinical management needs and potential treatment uptake patterns that influence overall market size and growth projections. Early AMD, characterized by small or few medium-sized drusen with minimal visual impact, represents the largest patient population but presents challenges for therapeutic intervention given slow progression rates, difficulty demonstrating clinical benefit within reasonable trial durations, and ethical considerations regarding treatment risk-benefit profiles for patients with preserved vision. Intermediate AMD, featuring extensive medium drusen or one or more large drusen potentially accompanied by retinal pigmentary changes, represents a critical intervention window where disease-modifying treatments might prevent progression to advanced stages, making this population particularly attractive for therapeutic development and likely to represent initial approved indications for emerging pharmacological treatments.